News

PPD's X-Chem pairs up with Alexion for drug discovery

X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.

INC Research lends its weight to trial site advocacy group

INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.

Catalent signs on to help Sellas get a repurposed drug to the finish line

Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.

Recipharm cues job cuts as a long-time partner drops out

Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.

WuXi moves to list a subsidiary on the Chinese market

WuXi PharmaTech is moving toward an IPO for one of its R&D and manufacturing subsidiaries, hoping to take advantage of a new market in its native China.

EU nations yank drugs over GVK data scandal

Some European Union states have suspended the approvals of drugs tied to a data falsification scandal at CRO GVK Biosciences, and the European Medicines Agency is investigating whether to recommend a continental halt.

Quintiles pools postmarketing services into a single offering

Quintiles has unveiled a new offering that combines its pharmacovigilance, label management, risk-benefit research and analytics into a single product, touting the service as a catch-all for approved drugs.

GVK gets its drug repurposing tech into Japan with new partnership

Indian CRO GVK Biosciences has signed a deal with a Japanese outfit to market its drug repurposing services in the country, part of the company's plot to diversify its revenue sources.

WuXi pairs up with deCODE spinout to further its genomics expansion

WuXi PharmaTech has spent the last year and change amping up its genomics expertise, and now China's largest CRO has signed a deal with Cambridge, MA's NextCODE Health to further grow its bioinformatics offerings.

Almac partners up to keep patients--and data--safe in trial emergencies

Pharma outsourcer Almac has signed a deal that allows it to add emergency services to its clinical trial management platform, allowing sponsors to quickly handle unforeseen problems and minimize the need for unblinding data, the company said.

Accovion reaches into France amid expansion kick

Fast-growing German CRO Accovion has made its way into France, opening up a new subsidiary as it works to become Europe's biggest independent pharma outsourcer.

Recipharm makes another buy to scale up its European might

Swedish contract drug developer Recipharm has signed a deal to extend its reach into France, buying a new facility and partnering with a local firm.

Feds want more trial results made public

The Department of Health and Human Services and the National Institutes of Health are proposing new rules that would greatly expand the number of clinical trials required to publicize their results, a move that could change how CROs handle data.

Medidata and TransCelerate beat the drum for risk-based monitoring

Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.

PRA and INC trade up amid a warm reception for CRO debuts

PRA Health Sciences and INC Research have both seen their shares tick upward since pulling off IPOs earlier this month, a sign that, despite biotech's boom and bust, the window for CRO debuts remains open.

Parexel recruits NextDocs to its stable of eClinical collaborators

NextDocs, a venture-backed document-management company, has signed a deal with Parexel to integrate its services with the CRO's growing eClinical platform.

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.

CRO Ricerca stays alive after buyer swoops in

Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.

Devicemaker Consort buys into the CDMO space with Aesica deal

The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices.

Recipharm trades $140M for a Portuguese CDMO

Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.